In 2016, CELLINK commercialized the world’s first bioink, a biomaterial innovation eight years within the making. That milestone was the primary of many alongside the corporate’s four-year journey to develop into the world’s main bioprinting firm with methods used to optimize cell-based functions for greater than 1,000 scientists throughout greater than 55 international locations.
The corporate develops each bioprinters and bioprinting supplies for offering ready-to-print or use fashions for researchers and healthcare suppliers to allow 3D cell tradition, personalised drugs, and enhanced therapeutics. The corporate focuses on three core utility areas: bioprinting, evaluation and liquid dealing with/bioprocessing and it has been designing and buying complementary applied sciences inside these fields.
Discover out extra about CellLink Life Sciences by clicking here.